

## Scientific Division (SD)

## Chair Prof. Philippe GILLERY

Lab. de Biologie et de Recherche Pédiatriques Hôpital Maison Blanche - CHU de Reims 45 Rue Cognacq Jay 51092 Reims Cedex - France Tel: +33 3 2678 3952 / Fax: +33 3 2678 3882 E-mail: pgillery@chu-reims.fr

### Vice-Chair Prof. Christa M. COBBAERT

Clinical Chemist Head of the Department of Clinical Chemistry Leiden University Medical Center Postbus 9600, Postzone E2-P 2300 RC Leiden - The Netherlands Tel: +31 71 5262278/+31 71 5264483 Fax: +31 71 52666753. ert@lumc.nl

### Secretary

Mr. Joseph PASSARELLI Scientific Relations Roche Diagnostics Corporation Research and Development 9115 Hague Road, PO Box 50457 Indianapolis, Indiana 46250-0457 - USA Tel: +1 317 521 4206 / Fax: +1 317 521 4103 Mobile / Cell: 1-317-625-7810 E-mail: joseph.pa arelli@roche.com

#### Members

#### Dr. Konstantinos MAKRIS

Clinical Biochemist Clinical Biochemistry Department KAT General Hospital 2 Nikis street, 14561 Kifissia, Athens - Greece Tel: +30-213-2086701 / Mobile: +30-6972207867 E-mail: kostas.makris.km@gmail.com

#### Prof. Tsutomu NOBORI

Professor Emeritus, Mie University Oyamada Memorial Spa Hospital 5538-1 Yamada-cho, Yokkaichi Mie 512-1111 - Japan Tel: (+81) 59-328-1260 / Fax: (+81)59-328-1921 E-mail: nobori@clin.medic.mie-u.ac.jp

# Prof. Mario PLEBANI

Full Professor of Clinical Biochemistry and Clinical Molecular Biology Chief Department of Laboratory Medicine University Hospital - Padova Dean of the Medical School University of Padova – Italy E-mail: mario.plebani@unipd.it

### Corporate Representative Mr. James F. PIERSON-PERRY

Principal Key Expert Global Assay Development, Glasgow Site Siemens Healthcare Diagnostics - USA Tel: +302.631.7692 / Cel: +302.229.6462 Fax: +302.631.7487 E-mail: James.f.pierson-perry@siemens-

ers.com

# JCTLM Consultant

Dr. Gary L. MYERS Chair, JCTLM 4711 Derby Lane Smyrna, GA 30082 –USA Tel: +404-457-5804 E-mail: gmyers1049@yahoo.com

# **European Commission -**JRC Observe

# Dr. Heinz SCHIMMEL Project Officer

Directorate General Joint Research Centre Reference Materials Unit Retieseweg 111 2440 Geel – Belgium Tel: +32 (0)14 571 720 E-mail: heinz.schimmel@ec.europa.eu

# **NIST Consultant**

### Dr. Karen W. PHINNEY

Leader, Bioanalytical Science Group Biomolecular Measurement Division National Institute of Standards and Technology (NIST) 100 Bureau Drive, Stop 8314 Gaithersburg, MD 20899-8314 - USA Tel: +1 (301) 975-44577 E-mail: karen.phinney@nist.gov

# **NIBSC Consultant**

# Dr. Chris BURNS

Head, Biotherapeutics Division National Institute for Biological Standards and Control - A Centre of the MHRA Blanche Lane, South Mimms, Potters Bar Hertfordshire, EN6 3QG, UK Tel: 01707 641247 E-mail: Chris.Burns@nibsc.org

Prof. Philippe Gillery, IFCC SD Chair From:

**November 23rd, 2017** Date:

Ref.: 8.2.25 - Committee on Standardization of Thyroid Function Tests

(C-STFT) - Membership

### To: All National Representatives of the Full and Affiliate Members **All Corporate Members**

Dear Colleagues,

The Committee on Standardization of Thyroid Function Tests (C-STFT), under the chairmanship of Prof. Linda Thienpont, intends to replace 4 members who have completed their term of office.

The specific *Terms of Reference* of this Committee are:

- Develop reference measurement systems (reference materials/reference methods) to establish traceability of free thyroid hormone and TSH assays.
- Establish a network of laboratories competent to offer reference measurement services for free thyroid hormones.
- Provide an infrastructure for procurement of serum panels.
- Demonstrate that the traceable assays can use a common reference interval; use this as a basis for further elaboration of the reference intervals by the IVD manufacturers; consult with clinicians about the need for ethnic, age- or sub-population-specific reference intervals in co-operation with C-RIDL.
- Liaise with key stakeholders to implement the use of the traceable assays in routine clinical practice.
- Through collaboration with IFCC EMD, provide educational materials for manufacturers, clinicians and patients which will support the implementation of traceable assays.

### Current Projects:

- Recalibration of FT4 and TSH assays after the Phase IV method comparison studies on clinically relevant samples: is intended as technical standardization/harmonization process, by which FT4 assays will become traceable to the conventional reference measurement procedure based on equilibrium dialysis (ED) isotope dilution-liquid chromatography-/tandem mass spectrometry (ID-LC/MS/MS), TSH assays to the statistically inferred all-procedure trimmed mean (APTM).
- Measure a FT4 and TSH panel of each 120 American apparently healthy volunteers with the recalibrated assays; measure the FT4 panel also with the conventional reference measurement procedure; use the data as proof-of-concept for standardization of FT4 and harmonization of TSH by demonstrating that the traceable assays can use a common reference interval; use this as a basis for further elaboration of the reference intervals by the IVD manufacturers.
- Get into contact with all involved stakeholders for benefit-risk analysis in preparation of the implementation of the standardized/harmonized assays.
- Promotion of the concept of Traceability in Latin America

Nominations should be directly sent to the IFCC Office (paola.bramati@ifcc.org) using the attached Application Form by December 20th, 2017.

Following approval, the candidates will be appointed for a three-year term (commencing January 2018). A second three-year term is allowed following satisfactory review at the end of the first term by the Scientific Division Executive Committee following consultation with the C-STFT Chairman.

Information on the current composition of the C-STFT and its activities are available on the IFCC Website, under Scientific Activities. More specific information can be obtained directly from Prof. Linda Thienpont (Linda.Thienpont@UGent.be).

Sincerely yours

Prof. Philippe Gillery Chair Scientific Division